 | |  | |  | |  | |  | |  | |  | |  |
| Dr. Beth Hartog |
Dr. Beth Hartog has joined our patient care team as the first woman infertility specialist based in
Monmouth and Ocean Counties! Dr. Hartog is board certified in Reproductive Endocrinology and
Infertility. She received her MD from New York Medical College in 1991. Dr. Hartog completed her
fellowship training at The George Washington University and remained at the University from 1997 to
2003 as the director of the University’s IVF program. She was instrumental in developing George
Washington’s IVF program into one of the premier programs in the country.
From 2003 to 2009, Dr. Hartog developed Maine’s first IVF program at Maine Medical Center. Dr.
Hartog’s focus as the director was establishing protocols that increased pregnancy rates while
minimizing the amount of necessary treatment. Dr. Hartog’s IVF program at Maine Medical Center
achieved pregnancy rates significantly higher than national averages.
One of Dr. Hartog’s key responsibilities during the last 15 years has been the education of medical
students, residents, and attending physicians. Her academic appointments include teaching and
research positions at the University of Vermont Medical School, Dartmouth Medical School and The
George Washington University.
Monmouth and Ocean Counties! Dr. Hartog is board certified in Reproductive Endocrinology and
Infertility. She received her MD from New York Medical College in 1991. Dr. Hartog completed her
fellowship training at The George Washington University and remained at the University from 1997 to
2003 as the director of the University’s IVF program. She was instrumental in developing George
Washington’s IVF program into one of the premier programs in the country.
From 2003 to 2009, Dr. Hartog developed Maine’s first IVF program at Maine Medical Center. Dr.
Hartog’s focus as the director was establishing protocols that increased pregnancy rates while
minimizing the amount of necessary treatment. Dr. Hartog’s IVF program at Maine Medical Center
achieved pregnancy rates significantly higher than national averages.
One of Dr. Hartog’s key responsibilities during the last 15 years has been the education of medical
students, residents, and attending physicians. Her academic appointments include teaching and
research positions at the University of Vermont Medical School, Dartmouth Medical School and The
George Washington University.
Dr. Hartog strives to provide a gentle and caring approach to patient exams and procedures. Her patients often comment on how painless they are. She is a
great listener and enjoys spending time answering all of the questions and concerns that her patients and their partners have during their consultations. Dr.
Hartog’s primary focus is to minimize the amount of treatment necessary to help her patients achieve their pregnancy goals.
Where there is great love there are always miracles.
~Willa Cather
Dr. Hartog's Publications
Riozin-Towle L, Meltzer HL, Hall EJ, Bigalow JC and Hartog B: Hypoxia mediated drugs and chemosensitization. Presented at 24th Annual Scientific
Meeting of the American Society of Therapeutic Radiologists. Kissimee, Florida, October 25-29, 1982.
Astor, MB, Parham JC, Hall EJ, Templeton MA and Hartog B: A 3-nitro triazole as a hypoxic cell sensitizer. British Journal of Cancer. 47: 155-157, 1983.
Astor MB, Hall EJ, Bigalow JC and Hartog B: In Vitro studies with two human cell lines deficient in glutathione. Seventh International Congress of
Radiation Research. Amsterdam, The Netherlands, July 3-8, 1983.
Riozin-Towle L, Hall EJ, Meltzer HL and Hartog B: Chemosensitization In Vitro. Thirty-Second Annual Meeting of the Radiation Research Society,
Orlando, Florida, March 25-29, 1984.
Astor MB, Hall EJ, and Hartog B: Thiols and radiosensitivity. Abstracts of Thirty-Second Annual Meeting of the Radiation Research Society. Orlando,
Florida, March 25-29, 1984.
Cruz J, Dubey A, Hartog B and Gindoff P: Is blastocyst transfer useful as an alternative treatment for IVF patients with previous IVF failure? Abstract P-
355, Proceedings of the Annual Meeting of the American Society of Reproductive Medicine, October 1998.
Stratton P, Hartog B, Hajizadeh N, Piguion J, Sutherland D, and Nieman LK. Effect of single mid-follicular dose of the CDB 2914, a new anti-progestin,
on folliculogenesis. Abstract 0-105, Proceedings of the 54th Annual Meeting of the American Society of Reproductive Medicine. San Francisco,
California, October 4-9, 1998.
Hartog B, Gindoff P. Opiod Peptides and Reproduction. The Endocrinologist, 8:1, 1998.
Dubey AK, Cruz J, Hartog B and Gindoff PR. Serum collected on the day of embryo transfer from patients undergoing IVF shows toxic effect on
development of mouse blastocyst. Abstract P-095, Proceedings of the 11th World Congress on IVF and Human Reproductive Genetics. Sydney,
Australia, May, 1999.
Dubey AK, Cruz J, Hartog B and Gindoff PR. Integrin adhesions molecules expression during development of preimplantation human embryos. 55th
Annual Meeting of ASRM, September 25-29th, Toronto, Canada, 1999.
Dubey AK, Nater, C, Sutherland, ML, Peak, D Hartog B, and Gindoff, PR. Apotosis in human: Expression of p53 in human preimplantation embryo.
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Department of Pharmacology; George Washington University
Medical Center, Washington, DC USA, IVF World Congress 2001.
Stratton P, Hartog B, Hajizadeh JP, Sutherland D, Merino M, Lee JY, and Nieman LK. A single mid-Follicular dose of CDB – 2914, a new antiprogestin
inhibits colliculogenesis and endometrial differentiation in normally cycling women. Human Reproduction. 15: 1092-1099.
Dubey A, Cruz J, Hartog B, Gindoff PR. Expression of the V Integrin Adhesion Molecule during Development of Preimplantation Human Embryos.
Fertility and Sterility. 76, July 2001.
Stratton P. Levens ED, Hartog B, Piquion J, Wei Q, Merino M, Nieman LK, Endometrial effects of a single early luteal dose of selective progesterone
receptor modulator CDB-2914. Fertility and Sterility. Feb 2009
Dr. Hartog's Research
Bazedoxifine acetate/CE 3115a1 303 US, Wyeth
Bazedoxifine acetate/CE 3115a1 305 US, Wyeth
Bazedoxifine acetate/CE 3115a1 337 US, Weyth
Leutrepatch Ferring
Chromosomal Aberrations and Integrin Expression During Early Human Embryo Development.
IRB# 129705 “Extent of Paternal and maternal chromatin decondensation in oocytes that failed to fertilize following ICSI in Human.”
IRB #109911ER: Multicenter project from Embryotech labs inc. “Fertil MARQ home diagnostic screening test comaparison study of lay users versus
clinical laboratory technician.
IRB#060021 Apoptosis in human: Expression of p53 in Human Preimplantation Embryo.
Refreezing of Thawed sperm samples: Sperm motility recovery after repetitive freezing and thawing.
Identification of Somato statin Receptors in Endometrial Tissue.
Perceptions and barriers women have about hormone replacement therapy. (IRB#099916ER)
Initial day and duration of Antagon Treament: Effect on IVF outcome. (IRB #020145)
Dubey A, Pinkusovich Y, Peak D, Hartog B, Gindoff P. Development of Human Blastocysts in Various Commercially Available Media.
A randomized, placebo-controlled, double-blind, parallel-group clinical study to assess the effects of nine months of repeated daily oral 1000mg BID
and 2000mg BID doses of INS-1 on the ovulatory, endocrine and metabolic abnormalities of women with Polycystic Ovarian Syndrome (PCOS).
North, Central and South Jersey Fertility Center
great listener and enjoys spending time answering all of the questions and concerns that her patients and their partners have during their consultations. Dr.
Hartog’s primary focus is to minimize the amount of treatment necessary to help her patients achieve their pregnancy goals.
Where there is great love there are always miracles.
~Willa Cather
Dr. Hartog's Publications
Riozin-Towle L, Meltzer HL, Hall EJ, Bigalow JC and Hartog B: Hypoxia mediated drugs and chemosensitization. Presented at 24th Annual Scientific
Meeting of the American Society of Therapeutic Radiologists. Kissimee, Florida, October 25-29, 1982.
Astor, MB, Parham JC, Hall EJ, Templeton MA and Hartog B: A 3-nitro triazole as a hypoxic cell sensitizer. British Journal of Cancer. 47: 155-157, 1983.
Astor MB, Hall EJ, Bigalow JC and Hartog B: In Vitro studies with two human cell lines deficient in glutathione. Seventh International Congress of
Radiation Research. Amsterdam, The Netherlands, July 3-8, 1983.
Riozin-Towle L, Hall EJ, Meltzer HL and Hartog B: Chemosensitization In Vitro. Thirty-Second Annual Meeting of the Radiation Research Society,
Orlando, Florida, March 25-29, 1984.
Astor MB, Hall EJ, and Hartog B: Thiols and radiosensitivity. Abstracts of Thirty-Second Annual Meeting of the Radiation Research Society. Orlando,
Florida, March 25-29, 1984.
Cruz J, Dubey A, Hartog B and Gindoff P: Is blastocyst transfer useful as an alternative treatment for IVF patients with previous IVF failure? Abstract P-
355, Proceedings of the Annual Meeting of the American Society of Reproductive Medicine, October 1998.
Stratton P, Hartog B, Hajizadeh N, Piguion J, Sutherland D, and Nieman LK. Effect of single mid-follicular dose of the CDB 2914, a new anti-progestin,
on folliculogenesis. Abstract 0-105, Proceedings of the 54th Annual Meeting of the American Society of Reproductive Medicine. San Francisco,
California, October 4-9, 1998.
Hartog B, Gindoff P. Opiod Peptides and Reproduction. The Endocrinologist, 8:1, 1998.
Dubey AK, Cruz J, Hartog B and Gindoff PR. Serum collected on the day of embryo transfer from patients undergoing IVF shows toxic effect on
development of mouse blastocyst. Abstract P-095, Proceedings of the 11th World Congress on IVF and Human Reproductive Genetics. Sydney,
Australia, May, 1999.
Dubey AK, Cruz J, Hartog B and Gindoff PR. Integrin adhesions molecules expression during development of preimplantation human embryos. 55th
Annual Meeting of ASRM, September 25-29th, Toronto, Canada, 1999.
Dubey AK, Nater, C, Sutherland, ML, Peak, D Hartog B, and Gindoff, PR. Apotosis in human: Expression of p53 in human preimplantation embryo.
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Department of Pharmacology; George Washington University
Medical Center, Washington, DC USA, IVF World Congress 2001.
Stratton P, Hartog B, Hajizadeh JP, Sutherland D, Merino M, Lee JY, and Nieman LK. A single mid-Follicular dose of CDB – 2914, a new antiprogestin
inhibits colliculogenesis and endometrial differentiation in normally cycling women. Human Reproduction. 15: 1092-1099.
Dubey A, Cruz J, Hartog B, Gindoff PR. Expression of the V Integrin Adhesion Molecule during Development of Preimplantation Human Embryos.
Fertility and Sterility. 76, July 2001.
Stratton P. Levens ED, Hartog B, Piquion J, Wei Q, Merino M, Nieman LK, Endometrial effects of a single early luteal dose of selective progesterone
receptor modulator CDB-2914. Fertility and Sterility. Feb 2009
Dr. Hartog's Research
Bazedoxifine acetate/CE 3115a1 303 US, Wyeth
Bazedoxifine acetate/CE 3115a1 305 US, Wyeth
Bazedoxifine acetate/CE 3115a1 337 US, Weyth
Leutrepatch Ferring
Chromosomal Aberrations and Integrin Expression During Early Human Embryo Development.
IRB# 129705 “Extent of Paternal and maternal chromatin decondensation in oocytes that failed to fertilize following ICSI in Human.”
IRB #109911ER: Multicenter project from Embryotech labs inc. “Fertil MARQ home diagnostic screening test comaparison study of lay users versus
clinical laboratory technician.
IRB#060021 Apoptosis in human: Expression of p53 in Human Preimplantation Embryo.
Refreezing of Thawed sperm samples: Sperm motility recovery after repetitive freezing and thawing.
Identification of Somato statin Receptors in Endometrial Tissue.
Perceptions and barriers women have about hormone replacement therapy. (IRB#099916ER)
Initial day and duration of Antagon Treament: Effect on IVF outcome. (IRB #020145)
Dubey A, Pinkusovich Y, Peak D, Hartog B, Gindoff P. Development of Human Blastocysts in Various Commercially Available Media.
A randomized, placebo-controlled, double-blind, parallel-group clinical study to assess the effects of nine months of repeated daily oral 1000mg BID
and 2000mg BID doses of INS-1 on the ovulatory, endocrine and metabolic abnormalities of women with Polycystic Ovarian Syndrome (PCOS).
North, Central and South Jersey Fertility Center
Please join Dr. Miguel Damien in
Welcoming Dr. Beth Hartog!
Welcoming Dr. Beth Hartog!
Questions?? Please Contact Us At 732-758-6511